Justin Kim
Stock Analyst at Oppenheimer
(0.86)
# 3,763
Out of 4,876 analysts
36
Total ratings
35.71%
Success rate
-14.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $17.43 | +129.49% | 6 | Nov 6, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $38 → $42 | $17.59 | +138.77% | 4 | Sep 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $33.16 | +219.66% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $31.15 | +179.29% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $22.65 | +14.79% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $3.79 | - | 2 | Oct 17, 2023 | |
| ZURA Zura Bio | Initiates: Outperform | $17 | $1.05 | +1,519.05% | 1 | Aug 25, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $8.64 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $9.36 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $39.80 | +48.24% | 1 | Jul 18, 2022 |
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $17.43
Upside: +129.49%
Pharvaris
Sep 6, 2024
Maintains: Outperform
Price Target: $38 → $42
Current: $17.59
Upside: +138.77%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $33.16
Upside: +219.66%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $31.15
Upside: +179.29%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $22.65
Upside: +14.79%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.79
Upside: -
Zura Bio
Aug 25, 2023
Initiates: Outperform
Price Target: $17
Current: $1.05
Upside: +1,519.05%
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.64
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.36
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $39.80
Upside: +48.24%